Life's essential 8 and mortality in US adults with metabolic dysfunction-associated steatotic liver disease

被引:0
|
作者
Zhang, Yingying [1 ]
Wang, Pingping [2 ]
Tu, Fan [1 ]
Kang, Hao [3 ]
Fu, Chengfeng [4 ]
机构
[1] Jiangnan Univ, Affiliated Wuxi Hosp 5, Med Lab Ctr, 1215 Guangrui Rd, Wuxi 214005, Jiangsu, Peoples R China
[2] Yangzhou Univ, Taizhou Peoples Hosp 2, Dept Clin Lab, Taizhou, Jiangsu, Peoples R China
[3] Jiangnan Univ, Affiliated Wuxi Hosp 5, Res Ctr Clin Med Sci, Wuxi, Jiangsu, Peoples R China
[4] Second Peoples Hosp Banan Dist, Resp & Crit Care Med, 18 Huaxi New Village,Huaxi St, Chongqing 400054, Peoples R China
关键词
MASLD; Life's essential 8; All-cause mortality; CVD mortality; National health and nutrition examination survey; AMERICAN HEART ASSOCIATIONS; CARDIOVASCULAR HEALTH; METAANALYSIS; OUTCOMES; METRICS; NHANES; RISK;
D O I
10.1186/s12889-024-20919-6
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) is linked to increased all-cause mortality due to metabolic dysfunctions like obesity, diabetes, and cardiovascular diseases. This study examines the association between Life's Essential 8 (LE8) scores and both all-cause and cardiovascular disease (CVD) mortality in MASLD participants. Methods Data from 5,916 MASLD participants in the NHANES (2005-2018) were analyzed. Associations between LE8 scores and all-cause and CVD mortality were assessed using Cox proportional hazards models, with follow-up until December 31, 2019. Dose-response relationships and survival differences were evaluated using Kaplan-Meier survival curves and Restricted Cubic Spline models. Results Over a median follow-up of 7.6 years, moderate and high LE8 scores were associated with 33% (HR: 0.67; 95% CI: 0.56-0.79) and 47% (HR: 0.53; 95% CI: 0.33-0.84) lower risk of all-cause mortality, respectively, compared to low scores. For CVD mortality, the adjusted HRs were 0.56 (95% CI: 0.41-0.78) and 0.35 (95% CI: 0.12-1.0). Higher LE8 scores were significantly associated with reduced cumulative incidence of all-cause and CVD mortality (log-rank P < 0.001). A 10-point increase in health behavior scores, particularly in diet, physical activity, and nicotine exposure, was linked to an 11% reduction in all-cause mortality risk and an 11% reduction in CVD mortality risk. Among health factors, only blood glucose showed a significant association with CVD mortality. Conclusion Higher LE8 scores in MASLD patients are associated with lower mortality risk, suggesting the potential value of promoting cardiovascular health in this population. Further research is needed to confirm these associations.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Association between life's essential 8 and metabolic dysfunction-associated steatotic liver disease among US adults
    Wang, Zheng
    Huang, Bohan
    Ding, Yixuan
    Cao, Feng
    Li, Fei
    Li, Prof Fei
    ARCHIVES OF PUBLIC HEALTH, 2024, 82 (01)
  • [2] Metabolic dysfunction-associated steatotic liver disease in adults
    不详
    NATURE REVIEWS DISEASE PRIMERS, 2025, 11 (01):
  • [3] Metabolic dysfunction-associated steatotic liver disease in adults
    Huang, Daniel Q.
    Wong, Vincent W. S.
    Rinella, Mary E.
    Boursier, Jerome
    Lazarus, Jeffrey V.
    Yki-Jarvinen, Hannele
    Loomba, Rohit
    NATURE REVIEWS DISEASE PRIMERS, 2025, 11 (01):
  • [4] Association of life's essential 8 with all-cause and cause-specific mortality in metabolic dysfunction-associated steatotic liver disease
    Li, Xiang
    Zhang, Yi
    Gong, Junyi
    Ni, Xiang
    Yin, Junli
    Lv, Zheng
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [5] Metabolic Dysfunction-Associated Steatotic Liver Disease
    Ali, Sajjadh M. J.
    Lai, Michelle
    ANNALS OF INTERNAL MEDICINE, 2025, 178 (01) : ITC1 - ITC17
  • [6] Associations of Cannabis Use, Metabolic Dysfunction-Associated Steatotic Liver Disease, and Liver Fibrosis in US Adults
    Wu, Yu
    Fang, Fei
    Fan, Xingliang
    Nie, Hongming
    CANNABIS AND CANNABINOID RESEARCH, 2024,
  • [7] Estimated Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease in US Adults, 2020 to 2050
    Le, Phuc
    Tatar, Moosa
    Dasarathy, Srinivasan
    Alkhouri, Naim
    Herman, William H.
    Taksler, Glen B.
    Deshpande, Abhishek
    Ye, Wen
    Adekunle, Olajide A.
    Mccullough, Arthur
    Rothberg, Michael B.
    JAMA NETWORK OPEN, 2025, 8 (01)
  • [8] Association between the Life's essential 8 health behaviors score and all-cause mortality in patients with metabolic dysfunction-associated steatotic liver disease
    Han, Yan
    Tang, Jing
    Wu, Na
    Li, Zhao
    Ren, Hong
    Hu, Peng
    Chen, Zhiwei
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2025, 163
  • [9] Metabolic dysfunction-associated steatotic liver disease and the heart
    Driessen, Stan
    Francque, Sven M.
    Anker, Stefan D.
    Cabezas, Manuel Castro
    Grobbee, Diederick E.
    Tushuizen, Maarten E.
    Holleboom, Adriaan G.
    HEPATOLOGY, 2023,
  • [10] Metabolic dysfunction-associated steatotic liver disease and atherosclerosis
    Castillo-Nunez, Yulino
    Almeda-Valdes, Paloma
    Gonzalez-Galvez, Guillermo
    Arechavaleta-Granell, Maria del Rosario
    CURRENT DIABETES REPORTS, 2024, 24 (07) : 158 - 166